Status note Phase 1a healthy-volunteer topline reported October 2025. Global Phase 1b trials ongoing in celiac disease (approximately 70 patients) and eosinophilic esophagitis (50 patients). FDA Fast Track designation for celiac disease in patients on a gluten-free diet.
rosnilimab
Phase 2 · ActiveModality: monoclonal antibody (pathogenic T cell depleter)
Target PD-1
Indications
moderate-to-severe rheumatoid arthritis(Stage not disclosed)
Status note Phase 2b trial in RA achieved its primary endpoint at Week 12 (reported February 2025, updated June 2025) with deepening responses through six months. End-of-Phase 2 meeting with the FDA completed in the first quarter of 2026.
Partnerships Vanda Pharmaceuticals (exclusive global license for development and commercialization of imsidolimab; company retains milestone-payment rights via the spin-off separation agreement)
Indications
generalized pustular psoriasis(Stage not disclosed)
Status note Out-licensed to Vanda; two registration-enabling global Phase 3 trials (GEMINI-1, GEMINI-2) completed by the licensee.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
71,910
+71,910
0.07%
2026-08-14
Ikarian Capital
42,775
+42,775
0.14%
2026-08-14
Sphera Biotech
27,876
+27,876
0.08%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.